Showing 821-830 of 3390 results for "".
AK Burden and Progression Risk
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-burden-and-progression-risk/20134/Individuals with chronic sun damage are at higher risk of developing AK lesions. It is therefore essential that dermatologists emphasize early sun protection recommendations and address progression risks of AK with their patients. Faced with increasing burden of skin cancers, Joel L. Cohen, MD and AGuys, Don't Be Like Paul:Â PSA
https://practicaldermatology.com/topics/skin-cancer-photoprotection/guys-don-t-be-like-paul-psa/18924/Dr. Terrence Keaney created this PSA for his American Society for Dermatologic Surgery (ASDS) Future Leaders Network project. The first PSA and video focuses specifically on men and features Dr. Keaney. Data from the Skin Cancer Foundation cited by ASDS show that only 30 percent of American men areExpanding Indications for Neuromodulators and Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/expanding-indications-for-neuromodulators-and-fillers-/18626/Emerging science of neuromodulators and fillers are expanding the role of these agents in dermatology practice, according to Dee Anna Glaser, MD. An intriguing area of research, she said, is the use of neuromodulators in the treatment of scars, as well as at the time of surgery for scar prevention.Your Destination for the Latest Developments in #Dermatology in Print and Online
https://practicaldermatology.com/topics/practice-management/your-destination-for-the-latest-developments-in-dermatology-in-print-and-online/21135/Updates on Nitric Oxide As a Topical Anti-infective
https://practicaldermatology.com/topics/practice-management/updates-on-nitric-oxide-as-a-topical-anti-infective/21071/NO continues to show promise as a safe and effective topical treatment candidate for acne and other infectious dermatoses.Make Some Noise: Advocating for Access
https://practicaldermatology.com/topics/practice-management/make-some-noise-advocating-for-access/20401/DCAN seeks to improve access to dermatologic treatments.Conversations in Acne, Part 1
https://practicaldermatology.com/topics/acne-rosacea/conversations-in-acne-part-1/19867/As treatment options for acne expand, clinicians consider the potential to combine topical therapies or pair topicals with systemics, all while adhering to guidelines for care and prescribing antibiotics responsibly. In the first episode of this three-part series, host Neal Bhatia, MD speaks with HiWhy Consider Lasers?
https://practicaldermatology.com/topics/practice-management/why-consider-lasers/18863/Should younger dermatologists add devices to their practice? Laser expert Eric Bernstein, MD talks about the decision to embrace technology and explains how it can mold the future of those who have a passion for lasers and other energy-based devices. Watch other PD Asks videos with Eric BernsteinI knew I wanted to become a dermatologist when...
https://practicaldermatology.com/topics/practice-management/i-knew-i-wanted-to-become-a-dermatologist-when---opefutim/18682/PD Asks: When Yolanda Lenzy, MD was about 13 years old she visited the office of Dr. Lynn McKinley Grant in Washington, DC. It was her first experience with an African American physician, and Dr. Lenzy describes how Dr. McKinley Grant inspired and supported her aspirations. Watch other responses toDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)